niacin has been researched along with Hyperglycemia in 16 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The widely used lipid-lowering drug niacin is reported to induce hyperglycemia during chronic and high-dose treatments, but the mechanism is poorly understood." | 7.81 | Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. ( Boucher, BJ; Chen, L; Cheng, Q; Leung, PS; Li, SY; So, WY, 2015) |
| "The widely used lipid-lowering drug niacin is reported to induce hyperglycemia during chronic and high-dose treatments, but the mechanism is poorly understood." | 3.81 | Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. ( Boucher, BJ; Chen, L; Cheng, Q; Leung, PS; Li, SY; So, WY, 2015) |
| "Niacin has beneficial effects on plasma lipoproteins and has demonstrated clinical benefits in reducing cardiovascular events and atherosclerosis progression." | 2.44 | Safety considerations with niacin therapy. ( Bays, HE; Guyton, JR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Tykhonenko, T | 1 |
| Guzyk, M | 1 |
| Tykhomyrov, A | 1 |
| Korsa, V | 1 |
| Yanitska, L | 1 |
| Kuchmerovska, T | 1 |
| Abdullah, KM | 1 |
| Qais, FA | 1 |
| Ahmad, I | 1 |
| Naseem, I | 1 |
| Masuda, Y | 1 |
| Kurikawa, N | 1 |
| Nishizawa, T | 1 |
| Chen, L | 1 |
| So, WY | 1 |
| Li, SY | 1 |
| Cheng, Q | 1 |
| Boucher, BJ | 1 |
| Leung, PS | 1 |
| Gorkin, JU | 1 |
| Watson, K | 1 |
| Knopp, RH | 1 |
| Cooper-DeHoff, RM | 1 |
| Pacanowski, MA | 1 |
| Pepine, CJ | 1 |
| Ledwidge, MT | 1 |
| Ryan, F | 1 |
| Kerins, DM | 1 |
| O'Connell, D | 1 |
| Cefali, G | 1 |
| Harmon, S | 1 |
| Jones, M | 1 |
| Gilmer, JF | 1 |
| SLUTZKY, L | 1 |
| Wang, M | 1 |
| Briggs, MR | 1 |
| Kishore, P | 1 |
| Tonelli, J | 1 |
| Koppaka, S | 1 |
| Fratila, C | 1 |
| Bose, A | 1 |
| Lee, DE | 1 |
| Reddy, K | 1 |
| Hawkins, M | 1 |
| Guyton, JR | 1 |
| Bays, HE | 1 |
| Schwartz, ML | 1 |
| Kahn, SE | 2 |
| McCulloch, DK | 1 |
| Schwartz, MW | 1 |
| Palmer, JP | 1 |
| Porte, D | 2 |
| Quabbe, HJ | 1 |
| Bunge, S | 1 |
| Walz, T | 1 |
| Bratzke, B | 1 |
| Johnston, P | 1 |
| Hollenbeck, C | 1 |
| Sheu, W | 1 |
| Chen, YD | 1 |
| Reaven, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients[NCT03973203] | 15 participants (Actual) | Interventional | 2014-06-01 | Completed | |||
| NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance[NCT04538521] | 3 participants (Actual) | Interventional | 2019-02-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacin and Hyperglycemia
| Article | Year |
|---|---|
Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Exercise; Fa | 2007 |
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2009 |
HDL: the metabolism, function, and therapeutic importance.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; ATP-Binding Cassette Transporters; Carrier Pr | 2004 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Safety considerations with niacin therapy.
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Chemistry, Pharmaceutical; Clinical | 2007 |
Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction?
Topics: Amyloid; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulinoma; | 1989 |
1 trial available for niacin and Hyperglycemia
| Article | Year |
|---|---|
Time-dependent effects of free fatty acids on glucose effectiveness in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluco | 2006 |
10 other studies available for niacin and Hyperglycemia
| Article | Year |
|---|---|
Modulatory effects of vitamin B3 and its derivative on the levels of apoptotic and vascular regulators and cytoskeletal proteins in diabetic rat brain as signs of neuroprotection.
Topics: Animals; Brain; Cytoskeletal Proteins; Diabetes Mellitus, Experimental; gamma-Aminobutyric Acid; Hyp | 2022 |
Inhibitory effect of vitamin B
Topics: Glucose; Glycation End Products, Advanced; Glycosylation; Humans; Hyperglycemia; Molecular Docking S | 2017 |
Overexpressing human GPR109A leads to pronounced reduction in plasma triglyceride levels in BAC transgenic rats.
Topics: Animals; Body Weight; Chromosomes, Artificial, Bacterial; Fatty Acids, Nonesterified; Gene Expressio | 2018 |
Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets.
Topics: Animals; Cell Line; Disease Models, Animal; Glucose; Hyperglycemia; Hypolipidemic Agents; Insulin; I | 2015 |
In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?
Topics: Animals; Apolipoproteins B; Aspirin; Blood Glucose; Chemistry, Pharmaceutical; Cholesterol, LDL; Cyc | 2012 |
[CONCOMITANCE OF HYPERGLYCEMIA WITH THE USE OF NICOTINIC ACID IN LARGE DOSES. STUDY IN DIABETICS].
Topics: Arteriosclerosis; Body Weight; Cholesterol; Diabetes Mellitus; Hyperglycemia; Lipid Metabolism; Niac | 1963 |
Severe reversible hyperglycemia as a consequence of niacin therapy.
Topics: Humans; Hypercholesterolemia; Hyperglycemia; Male; Middle Aged; Niacin | 1993 |
Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hyperglycemia; Insulin; Insulin Resistance; | 1992 |
Plasma glucose and free fatty acids modulate the secretion of growth hormone, but not prolactin, in the rhesus and Java monkey.
Topics: Animals; Blood Glucose; Fatty Acids, Nonesterified; Glucose; Growth Hormone; Haplorhini; Hydrocortis | 1990 |
Acute changes in plasma non-esterified fatty acid concentration do not change hepatic glucose production in people with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glu | 1990 |